Treatment of Digital Ulcers and Reflux Oesophagitis in a Patient with Systemic Sclerosis: Increased Risk of Hepatotoxicity due to a Potential Drug-drug Interaction Between Bosentan and Vonoprazan
DOI:
https://doi.org/10.2340/actadv.v101.439Keywords:
systemic scleroderma, bosentan, lansoprazole, vonoprazan fumarateAbstract
Abstract is missing (Short communication)
Downloads
References
Eriksson C, Gustavsson A, Kronvall T, Tysk C. Hepatotoxicity by bosentan in a patient with portopulmonary hypertension: a case-report and review of the literature. J Gastrointestin Liver Dis 2011; 20: 77-80.
Danan G, Benichou C. Causality assessment of adverse reactions to drugs - I. A method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1323-1330.
https://doi.org/10.1016/0895-4356(93)90101-6 DOI: https://doi.org/10.1016/0895-4356(93)90101-6
Tingey T, Shu J, Smuczek J, Pope J. Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis. Arthritis Care Res 2013; 65: 1460-1471.
https://doi.org/10.1002/acr.22018 DOI: https://doi.org/10.1002/acr.22018
Echizen H. The First-in-class potassium-competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet 2016; 55: 409-418.
https://doi.org/10.1007/s40262-015-0326-7 DOI: https://doi.org/10.1007/s40262-015-0326-7
Herszényi L, Bakucz T, Barabás L, Tulassay Z. Pharmacological approach to gastric acid suppression: past, present, and future. Dig Dis 2020; 38: 104-111.
https://doi.org/10.1159/000505204 DOI: https://doi.org/10.1159/000505204
Scarpignato C, Hunt RH. The potential role of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease. Curr Opin Gastroenterol 2019; 35: 344-355.
https://doi.org/10.1097/MOG.0000000000000543 DOI: https://doi.org/10.1097/MOG.0000000000000543
Srinivas NR. Clinical drug-drug interactions of bosentan, a potent endothelial receptor antagonist, with various drugs: physiological role of enzymes and transporters. Gen Physiol Biophys 2016; 35: 243-258.
https://doi.org/10.4149/gpb_2015050 DOI: https://doi.org/10.4149/gpb_2015050
Wang Y, Wang C, Wang S, Zhou Q, Dai D, Shi J, et al. Cytochrome P450-based drug-drug interactions of vonoprazan in vitro and in vivo. Front Pharmacol 2020; 11: 53.
https://doi.org/10.3389/fphar.2020.00053 DOI: https://doi.org/10.3389/fphar.2020.00053
Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet 2005; 20: 153-167.
https://doi.org/10.2133/dmpk.20.153 DOI: https://doi.org/10.2133/dmpk.20.153
Zvyaga T, Chang SY, Chen C, Yang Z, Vuppugalla R, Hurley J, et al. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19. Drug Metab Dispos 2012; 40: 1698-1711.
https://doi.org/10.1124/dmd.112.045575 DOI: https://doi.org/10.1124/dmd.112.045575
Ogilvie BW, Yerino P, Kazmi F, Buckley DB, Rostami-Hodjegan A, Paris BL, et al. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel. Drug Metab Dispos 2011; 39: 2020-2033.
https://doi.org/10.1124/dmd.111.041293 DOI: https://doi.org/10.1124/dmd.111.041293
Li X-Q, Andersson TB, Ahlström M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004; 32: 821-827.
https://doi.org/10.1124/dmd.32.8.821 DOI: https://doi.org/10.1124/dmd.32.8.821
Funakoshi R, Tomoda Y, Kudo T, Furihata K, Kusuhara H, Ito K. Effects of proton pump inhibitors, esomeprazole and vonoprazan, on the disposition of proguanil, a CYP2C19 substrate, in healthy volunteers. Br J Clin Pharmacol 2019; 85: 1454-1463.
https://doi.org/10.1111/bcp.13914 DOI: https://doi.org/10.1111/bcp.13914
Oshima T, Miwa H. Potent potassium-competitive acid blockers: a new era for the treatment of acid-related diseases. J Neurogastroenterol Motil 2018; 24: 334-344.
https://doi.org/10.5056/jnm18029 DOI: https://doi.org/10.5056/jnm18029
Ashida K, Sakurai Y, Hori T, Kudou K, Nishimura A, Hiramatsu N, et al. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther 2016; 43: 240-251.
https://doi.org/10.1111/apt.13461 DOI: https://doi.org/10.1111/apt.13461
Shimizu T, Ochiai H, Asell F, Shimizu H, Saitoh R, Hama Y, et al. Bioinformatics research on inter-racial difference in drug metabolism I. Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19. Drug Metab Pharmacokinet 2003; 18: 48-70.
https://doi.org/10.2133/dmpk.18.48 DOI: https://doi.org/10.2133/dmpk.18.48
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2021 Ryoko Kimura, Kazunari Sugita, Takaaki Sugihara, Hajime Isomoto
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
